Bayer's commitment

For more than three decades, Bayer has focused on delivering state-of-the-art treatment options for people living with haemophilia.

At Bayer we're following through on our pledge by investing millions every year to improve the lives of people living with haemophilia. Bayer currently funds research and a variety of educational and recreational services for haemophilia patients and their families. We also provide significant financial support to the programmes and initiatives of professional organisations, academic societies, safety councils, and patient advocacy groups.

ClinicalTrials.gov

Find out about ongoing trials in haemophilia by visiting ClinicalTrials.gov

Click here

Bayer Haemophilia Awards

For more information about the programme click here